Eric Winer, MD
Enriched profileDirector, Yale Cancer Center; President and Physician-in-Chief, Smilow Cancer Hospital; Alfred Gilman Professor of Pharmacology and Professor of Medicine; Deputy Dean for Cancer Research, Yale School of Medicine · Yale School of Medicine
Eric Winer is Director, Yale Cancer Center; President and Physician-in-Chief, Smilow Cancer Hospital; Alfred Gilman Professor of Pharmacology and Professor of Medicine; Deputy Dean for Cancer Research, Yale School of Medicine at Yale School of Medicine. OpenAlex indexes 1,624 publications with 130,977 citations (h-index 171); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Eric P. Winer is Director, Yale Cancer Center at Yale School of Medicine / Yale Cancer Center / Smilow Cancer Hospital, New Haven, CT. The public record shows 1,624 publications with 130,977 citations (h-index 171), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology. It also documents an investigator role on 8 registered clinical trials, 2 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Breast Cancer Treatment Studies
- 8 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 56 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 666.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- As ASCO leadership (President/Board Chair)
publicly urged Congress to prioritize and continue funding for federal cancer research (NIH, NCI, ARPA-H) in FY2025/FY2026 appropriations …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →asco.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →insights.som.yale.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Sponsor: UNC Lineberger Comprehensive Cancer Center
- A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Sponsor: SOLTI Breast Cancer Research Group
Industry payments
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- PUMA BIOTECHNOLOGY, INC.Program year20252 payments
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Ibrance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)
Yale University
FY2026$587,002T32CA233414
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
Journal of the National Cancer Institute
Article2026 - Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
Journal of the National Cancer Institute
Article2025
Most-cited works
by citation count (OpenAlex)- 01Breast Cancer Treatment4,866 citations2019
- 02Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer4,374 citations2018
- 03
- 04
- 05Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer2,014 citations2016
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/eric-winer-md-9c96eed0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
insights.som.yale.edu/podcasts/health-veritas/eric-winer-cancer-doctors-journey
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →insights.som.yale.edu ↗ - Other
yalecancercenter.org/news/cancer-answers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalecancercenter.org ↗
Mentions by others
where others cite or feature them- X / Twitter
Yale Cancer Center official X account (@YaleCancer) references Dr. Winer as Director
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - Connection.asco.org
ASCO Connection: 'ASCO President-Elect Dr. Eric Winer Takes on New Leadership Role at Yale Cancer Center'
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗ - Bcrf.org
BCRF blog: 'BCRF Congratulates Dr. Eric P. Winer on Prestigious Appointment at Yale'
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- Internal Medicine Residency
Yale School of Medicine (1984-1987); Chief Resident, Yale New Haven Hospital
1987verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- Former Chief of Breast Oncology Program
Dana-Farber Cancer Institute (1997-2021); former Professor of Medicine, Harvard Medical School; former Senior VP for Medical Affairs, Dana-Farber …
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗ - Formerly Chief
Breast Oncology Program, Dana-Farber Cancer Institute (1997-2021); Professor of Medicine, Harvard Medical School
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗ - Chief Scientific Advisor
Susan G. Komen for the Cure (prior long-term role, over a decade)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →insights.som.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →conquer.org ↗
- Host
"Yale Cancer Answers" weekly podcast/radio program on Connecticut Public Radio (WNPR/WICC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalecancercenter.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Harlan Krumholz, MD
Yale School of Medicine
Roy Herbst, MD, PhD
Yale School of Medicine
Robert Rosenheck, MD
Yale School of Medicine
William Tamborlane, MD
Yale School of Medicine